NASDAQ · KALV
KalVista Pharmaceuticals, Inc.
$27.00$0.00 (0.0%)
KalVista Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
NASDAQ · CMPX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Compass Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.01% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Compass Therapeutics, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.12. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Compass Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$0.120.0% vs estimate |
| $0.00 |
| Q4 2024 | Feb 27, 2025 | -$0.11-10.0% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.08+27.27% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
17 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $4.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$27.00$0.00 (0.0%)
KalVista Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$18.95+$1.07 (+5.98%)
Omeros Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.78% below the high.
$10.23-$0.29 (-2.76%)
Corvus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.04% below the high.
$12.78-$0.15 (-1.16%)
4D Molecular Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.51% below the high.
$1.48-$0.01 (-0.34%)
Lexicon Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.78% below the high.
$71.91-$1.48 (-2.02%)
Monopar Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.39% below the high.
$3.77+$0.02 (+0.53%)
Fulcrum Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.05% below the high.
$3.82-$0.06 (-1.55%)
Bicycle Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 57.93% below the high.
